cervicorn consulting

Life Science Tools Market (By Technology: Genomic Technology, Proteomics Technology, Cell Biology Technology, Lab Supplies & Technologies, Other Analytical & Sample Preparation Technology; By Product: Cell Culture Systems & 3D Cell Culture, Liquid Chromatography, Mass Spectrometry, Flow Cytometry, Others By End-use: Government & Academic, Biopharmaceutical Company, Healthcare, Industrial Applications, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis And Forecast 2024 To 2033

Life Science Tools Market Size and Growth 2024 To 2033

The global life science tools market size was worth USD 153.40 billion in 2023 and is estimated to reach around USD 349.58 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.58% from 2024 to 2033.

Life Science Tools Market Size 2024 To 2033

The life science tools market consist of a range of products and technologies used in biological research, diagnostics, and therapeutic development, including instruments, reagents, consumables, and software. Key driving factors of this market include the rise in research and development activities, advancements in biotechnology and genomics, and the increasing demand for personalized medicine. Government funding and investments from pharmaceutical and biotech companies further fuel market growth. Additionally, technological innovations, such as high-throughput screening and next-generation sequencing, along with the growing prevalence of chronic diseases, is driving the need for advanced life science tools in various applications.

  • Gene therapy is used in the development of mRNA vaccines, such as those produced by Pfizer-BioNTech and Moderna. These vaccines direct cells to create a viral protein that elicits an immune response by introducing a tiny bit of genetic material (mRNA) into the cells.
  • In December 2021, The U.S. FDA granted Siemens Healthineers an Emergency Use Authorization for its COVID-19 quick test, the CLINITEST quick COVID-19 Antigen Self-Test, which is intended for use by anyone 14 years of age and older for self-testing. The market will be driven by government financing, ongoing product releases, new breakthroughs connected to the pandemic, and product approvals.
  • In January 2021, according to an article published by mAbxience, 27 monoclonal antibodies have been approved for treating different types of cancer as monoclonal antibodies are rapidly evolving in the field of cancer therapy. 

Report Highlights

  • North America region has captured dominating revenue share of 39.40% in 2023
  • Europe region has recorded second highest market revenue share of 28.70% in 2023.
  • By end-use, The healthcare segment has registered highest market revenue share of 32% in 2023.
  • By Technology, In 2023 the cell biology segment has accounted highest revenue share of 44.20%.

Life Science Tools Market Growth Factors

  • Advancements in Genomics and Biotechnology: Innovations in genomic sequencing, gene editing (e.g., CRISPR), and biotechnology are expanding research capabilities and applications, driving demand for sophisticated life science tools.
  • Rise in Research and Development Activities: Increasing investments in R&D by pharmaceutical, biotechnology companies, and academic institutions boost the need for advanced tools and technologies to support innovative research and drug development.
  • Personalized Medicine: The growing emphasis on personalized medicine, which tailors treatments to individual genetic profiles, necessitates advanced diagnostic and analytical tools, fueling market growth.
  • Technological Innovations: Continuous advancements in high-throughput screening, bioinformatics, and automation enhance research efficiency and accuracy, driving the adoption of cutting-edge life science tools.
  • Government Funding and Support: Increased government funding for scientific research and public health initiatives, particularly in genomics and biotechnology, supports the development and commercialization of new life science tools, accelerating market expansion.
  • Digitalization and AI Integration: The adoption of artificial intelligence (AI) and machine learning (ML) in life sciences is enhancing data analysis, drug discovery, and personalized medicine, driving the demand for advanced digital tools.
  • Next-Generation Sequencing (NGS): NGS technologies are becoming more accessible and affordable, revolutionizing genomics research and diagnostics with high-throughput and precise genetic analysis.
  • Single-Cell Analysis: Tools for single-cell genomics and proteomics are gaining traction, enabling detailed insights into cellular heterogeneity and advancing cancer research and developmental biology.
  • Lab Automation: Automation in laboratories, including robotic systems and automated workflows, is increasing efficiency, reducing errors, and accelerating research processes.
  • Point-of-Care Testing: The shift towards decentralized diagnostics and point-of-care testing is driving demand for portable and user-friendly life science tools.
  • Bioprocessing and Biomanufacturing: Advances in bioprocessing technologies support the production of biologics and cell and gene therapies, necessitating specialized tools and instruments.
  • Sustainability: There is a growing emphasis on environmentally friendly and sustainable practices in research and development, influencing the design and manufacturing of life science tools.

Report Scope

Area of Focus Details
Market Size in 2024 USD 166.57 Billion
Market Growth Rate CAGR of 8.58% from 2024 to 2033
Market Size by 2033 USD 349.58 Billion
Largest Market North America
Fastest Growing Market Asia Pacific
Segment Coverage By Technology, Product, End-use and Regions

Life Science Tools Market Dynamics

Drivers

Expanding Applications in Agricultural Biotechnology

  •  The use of life science tools in agricultural biotechnology is growing, driven by the need for enhanced crop yields and sustainable farming practices. Techniques like gene editing and plant genomics are increasingly being applied to develop pest-resistant, high-yield crops, fueling demand for advanced tools in this sector.

Aging Population and Chronic Diseases

  • The global increase in the aging population and the prevalence of chronic diseases are driving the need for advanced diagnostic and therapeutic tools. Life science tools are crucial in understanding age-related diseases and developing treatments, leading to heightened demand for innovative research instruments and technologies in medical research.

Restraints

High Costs of Advanced Technologies

  • The high costs associated with advanced life science tools, such as next-generation sequencing and automated systems, can be prohibitive for smaller research institutions and laboratories. This financial barrier limits widespread adoption and restricts market growth, particularly in developing regions with limited funding.

Regulatory and Compliance Challenges

  • The life science tools market faces stringent regulatory requirements and compliance standards that can slow down the development and commercialization of new products. Navigating these complex regulations requires significant time and resources, posing a challenge for companies and potentially delaying market entry for innovative tools and technologies.

Opportunities

Expansion in Emerging Markets

  • Growing investment in healthcare infrastructure and research capabilities in emerging markets presents significant opportunities. As countries like China and India enhance their biomedical research and diagnostics sectors, demand for advanced life science tools is set to rise, offering substantial growth potential for market players.

Advancements in Personalized Medicine

  • The increasing focus on personalized medicine, which tailors treatments to individual genetic profiles, opens new avenues for life science tools. This trend drives demand for sophisticated genomic and proteomic technologies, enabling precise diagnostics and targeted therapies, thereby expanding the market for innovative life science solutions.

Challenges

Data Management and Integration

  • Handling and integrating vast amounts of data generated by advanced life science tools is a significant challenge. Effective data management requires robust bioinformatics infrastructure and expertise, which can be resource-intensive and complex, hindering seamless research and analysis.

Intellectual Property and Patent Issues

  • Navigating intellectual property (IP) rights and patent regulations can be challenging for companies in the life science tools market. Disputes over IP ownership and the complexity of patent laws can lead to costly legal battles and hinder innovation, impacting market growth and collaboration efforts.

Life Science Tools Market Segmental Analysis

Technology Analysis

Genomic Technology: Genomic technologies in the Life Science Tools market, such as next-generation sequencing (NGS) and microarray analysis, are pivotal for studying genetic variations, gene expression, and genome structure. This segment has achieved market share of 16.70% in 2023. Trends include the adoption of single-cell sequencing for heterogeneous cell populations and the integration of NGS with bioinformatics for comprehensive genomic analysis. Drivers include decreasing costs of sequencing, advancements in bioinformatics algorithms for data interpretation, and the growing applications in personalized medicine, agriculture, and environmental studies.

Life Science Tools Market Share, By Technology, 2023 (%)

Proteomics Technology: Proteomics technologies focus on the study of proteins, crucial for understanding biological functions, disease mechanisms, and drug responses. Trends include the adoption of mass spectrometry for high-throughput protein profiling and the development of protein microarrays for multiplexed biomarker discovery. In 2023 proteomics technology segment has reported market share of 20%. Drivers include advancements in mass spectrometry sensitivity and resolution, innovations in protein labeling and quantification techniques, and the increasing demand for precision medicine and biomarker-driven diagnostics.

Cell Biology Technology: Cell biology technologies encompass cell culture systems, flow cytometry, and cell imaging techniques critical for studying cell behavior and function. This segment has acquired highest market share of 44.20% in 2023. Trends include the shift towards 3D cell culture models for better physiological relevance and the integration of live-cell imaging for dynamic cellular analysis. Drivers include advancements in biomaterials for cell culture, automation of cell imaging platforms, and the application in drug discovery, regenerative medicine, and cancer research.

Lab Supplies & Technologies: Lab supplies and technologies encompass consumables, laboratory equipment, and automation solutions crucial for scientific research and diagnostic laboratories. Lab supplies & technologies segment has exceeded market share of 11% in 2023. Trends include the development of connected and automated laboratory systems, enhancing workflow efficiency and data management. Drivers include the global expansion of healthcare infrastructure, adoption of personalized medicine approaches, and the emphasis on sustainability and cost-effectiveness in laboratory operations.

Other Analytical & Sample Preparation Technology: This segment includes various technologies such as chromatography, spectrophotometry, and sample preparation techniques essential for analyzing biomolecules and isolating analytes. This segment has covered market share of 8.10% in 2023. Trends include the development of automated sample preparation systems and miniaturized analytical platforms for point-of-care testing. Drivers include the demand for faster and more accurate analytical methods, advancements in detection technologies, and the integration of multiple analytical techniques for complex sample analysis in clinical diagnostics and environmental monitoring.

Product Analysis

Cell Culture Systems & 3D Cell Culture: Cell culture systems and 3D cell culture technologies are pivotal in the Life Science Tools market for studying cellular behavior and responses to drugs. Trends include the increasing adoption of organoid models and bio-printing techniques to create more physiologically relevant models. Drivers include advancements in biomaterials, such as hydrogels and scaffolds, enabling better mimicry of human tissues, and the growing demand for personalized medicine and regenerative therapies.

Liquid Chromatography: Liquid chromatography (LC) plays a crucial role in separating and analyzing biomolecules in life science research, including proteins, peptides, and metabolites. Trends include the adoption of high-resolution LC systems and the integration of LC with mass spectrometry for comprehensive analysis. Drivers include the need for accurate quantification of biomarkers in drug discovery and clinical diagnostics, advancements in column technologies and detection methods, and the expanding applications in metabolomics and proteomics research.

Mass Spectrometry: Mass spectrometry (MS) is essential for identifying and quantifying biomolecules based on their mass-to-charge ratio, crucial for proteomics, metabolomics, and drug metabolism studies. Trends include the development of high-resolution MS systems and the integration of MS with LC for enhanced analytical capabilities. Drivers include improvements in ionization techniques, software for data analysis, and the increasing adoption in clinical laboratories for disease biomarker profiling and therapeutic drug monitoring.

Flow Cytometry: Flow cytometry enables the analysis of cells and particles based on their physical and chemical properties, essential for immunology, cancer research, and hematological studies. Trends include the adoption of multiparametric flow cytometry and the development of imaging flow cytometry for high-content analysis. Drivers include advancements in fluorophore technology, automated sample handling systems, and the expanding applications in cell sorting, cell signaling studies, and infectious disease research.

Cloning & Genome Engineering: Cloning and genome engineering technologies encompass methods for manipulating DNA and producing recombinant proteins in life science research. Trends include the adoption of CRISPR/Cas9 for precise genome editing and the development of synthetic biology tools for therapeutic applications. Drivers include the demand for personalized medicine, advancements in gene delivery technologies, and the application of genome editing in developing disease models and gene therapies.

Microscopy & Electron Microscopy: Microscopy techniques, including light microscopy and electron microscopy, provide detailed visualization of biological structures and processes. Trends include the adoption of super-resolution microscopy for nanoscale imaging and the integration of live-cell imaging techniques for dynamic studies. Drivers include improvements in imaging resolution, automated imaging platforms, and the application of advanced microscopy in neuroscience, pathology, and microbiology research.

Next Generation Sequencing (NGS): NGS technologies enable rapid sequencing of DNA and RNA, revolutionizing genomics and molecular diagnostics. Trends include the adoption of whole genome sequencing and RNA sequencing for comprehensive genomic profiling and transcriptome analysis. Drivers include cost reductions in sequencing, advancements in bioinformatics tools for data analysis, and the expanding applications in oncology, infectious diseases, and rare genetic disorders.

PCR & qPCR: Polymerase chain reaction (PCR) and quantitative PCR (qPCR) are fundamental for amplifying and quantifying nucleic acids in life science research, essential for genetic analysis and pathogen detection. Trends include the development of digital PCR for absolute quantification and the integration of multiplex PCR for simultaneous detection of multiple targets. Drivers include improvements in PCR sensitivity and speed, adoption in clinical diagnostics and environmental monitoring, and the demand for rapid and accurate molecular testing.

Nucleic Acid Preparation: Nucleic acid preparation technologies involve the extraction and purification of DNA and RNA from biological samples for downstream analysis. Trends include the development of automated systems for high-throughput processing and magnetic bead-based purification methods for enhanced purity. Drivers include the need for standardized sample preparation workflows, advancements in extraction chemistries, and the application in genetic testing, infectious disease diagnostics, and forensic sciences.

Nucleic Acid Microarray: Nucleic acid microarrays enable high-throughput analysis of gene expression, mutations, and polymorphisms in life science research. Trends include the adoption of microarray platforms for pharmacogenomics and personalized medicine applications and the development of multiplexed arrays for simultaneous detection of multiple targets. Drivers include advancements in microarray printing technologies, bioinformatics tools for data analysis, and the expanding role in biomarker discovery and disease profiling.

Sanger Sequencing: Sanger sequencing remains valuable for sequencing short DNA fragments with high accuracy, critical for genetic analysis and validation in life science research. Trends include the automation of Sanger sequencing workflows and integration with NGS platforms for hybrid sequencing approaches. Drivers include improvements in sequencing chemistry and detection sensitivity, adoption in clinical genetics and molecular diagnostics, and the application in forensic sciences and evolutionary biology.

Transfection Devices & Gene Delivery Technologies: Transfection devices and gene delivery technologies facilitate the introduction of nucleic acids into cells for gene editing and therapy applications. Trends include the development of non-viral delivery systems and CRISPR/Cas9-based tools for precise genome modifications. Drivers include advancements in biocompatible delivery vehicles, improvements in transfection efficiency, and the expanding use in developing gene therapies, cell-based vaccines, and genetically modified organisms.

NMR: Nuclear magnetic resonance (NMR) spectroscopy plays a critical role in analyzing molecular structures and interactions in life science research, particularly in metabolomics and drug discovery. Trends include the adoption of high-field NMR systems for enhanced sensitivity and multi-dimensional analysis. Drivers include advancements in NMR probe technology, software for data processing, and the application in studying protein-ligand interactions, metabolic pathways, and disease mechanisms.

Others: This segment includes emerging and specialized technologies in life science research, including digital pathology, biosensors, and microfluidics. Trends include the development of miniaturized diagnostic devices for point-of-care testing and wearable sensors for real-time health monitoring. Drivers include the demand for decentralized testing solutions, advancements in sensor technologies, and the application of novel platforms in remote and resource-limited settings.

End-use Analysis 

Government & Academic: Government and academic institutions are significant users of Life Science Tools, conducting research across various disciplines from basic science to applied research. This segment has registered market share of 20% in 2023. Trends include increasing funding for life sciences research, especially in genomics, proteomics, and infectious diseases. Drivers include government initiatives to promote scientific research, collaborations between academia and industry for translational research, and the demand for advanced tools to address global health challenges such as pandemics and climate change.

Life Science Tools Market Share, By End Use, 2023 (%)

Biopharmaceutical Company: Biopharmaceutical companies utilize Life Science Tools for drug discovery, development, and manufacturing of biologics and pharmaceuticals. Trends include the adoption of high-throughput screening technologies, automation in laboratory workflows, and advancements in bioprocessing technologies. The biopharmaceutical companies segment has covered market share of 24% in 2023. Drivers include the rising demand for personalized medicine, investments in biotechnology research, and regulatory pressures to improve drug safety and efficacy through advanced analytics and biomarker discovery.

Healthcare: The healthcare segment has recorded highest market share of 32% in 2023. Healthcare providers rely on Life Science Tools for clinical diagnostics, patient monitoring, and therapeutic decision-making. Trends include the integration of molecular diagnostics and point-of-care testing for rapid disease diagnosis and management. Drivers include the aging population driving demand for diagnostic tools, advancements in diagnostic imaging technologies, and the shift towards personalized and precision medicine approaches to improve patient outcomes and reduce healthcare costs.

Industrial Applications: Industries outside of healthcare, such as agriculture, food and beverage, and environmental monitoring, utilize Life Science Tools for quality control, environmental testing, and agricultural research. Trends include the adoption of rapid testing technologies, biosensors for environmental monitoring, and genetic tools for crop improvement. This segment has captured market share of 15% in 2023. Drivers include regulatory requirements for product safety and environmental protection, advancements in biotechnology for sustainable agriculture, and the need for efficient and reliable analytical methods in industrial settings.

Others: The otthers segment has accounted market share of 9% in 2023. This segment includes diverse sectors using Life Science Tools, including veterinary diagnostics, forensic sciences, and environmental research. Trends include the development of specialized tools for niche applications, such as wildlife conservation and forensic DNA analysis. Drivers include emerging infectious diseases necessitating rapid diagnostic tools, advancements in forensic technologies for crime investigation, and the growing importance of environmental sustainability driving demand for bioanalytical tools.

Life Science Tools Market Regional Analysis

Why North America is leading in the life science tools market?

North America dominates the Life Science Tools Market due to rapidly growing research infrastructure, high healthcare expenditure, and strong presence of key market players. North America market size is expected to reach around USD 137.73 billion by 2033 increasing from USD 65.63 billion in 2024. The region benefits from significant investments in biotechnology and pharmaceutical industries, driving innovation in genomics, proteomics, and personalized medicine.

North America Life Science Tools Market Size 2024 To 2033

Why Asia-Pacific is experiencing significant growth in the Life Science Tools Market?

Asia-Pacific is experiencing rapid growth in the Life Science Tools Market fueled by expanding healthcare infrastructure, rising investments in biotechnology, and increasing research collaborations. Countries like China, Japan, and India are leading the adoption of genomic technologies and diagnostic advancements, Asia Pacific market size is calculated at USD 38.14 billion in 2024 and is projected to grow around USD 80.05 billion by 2033. driven by growing healthcare needs and government initiatives promoting scientific innovation.

Europe Life Science Tools Market Trends

Europe is a key market for Life Science Tools with advanced healthcare systems, supportive regulatory frameworks, and substantial government funding for research. Europe market size is measured at USD 47.81 billion in 2024 and is expected to grow around USD 100.33 billion by 2033. The region emphasizes precision medicine and environmental sustainability, fostering growth in genomic research, clinical diagnostics, and biopharmaceutical manufacturing.

Life Science Tools Market Share, By Region, 2023 (%)

LAMEA Life Science Tools Market Trends

LAMEA represents an emerging market for Life Science Tools with improving healthcare infrastructure, increasing investments in healthcare R&D, and expanding pharmaceutical manufacturing capabilities. LAMEA market size is forecasted to reach around USD 31.46 billion by 2033 from USD 14.99 billion in 2024. The region shows potential for growth in clinical diagnostics, genetic testing, and agricultural biotechnology, supported by government initiatives to enhance healthcare access and address infectious diseases and chronic conditions.

Global Life Science Tools Market Top Companies

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA (EMD Millipore)
  • Agilent Technologies, Inc.
  • Danaher Corporation (Beckman Coulter)
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Bruker Corporation
  • Waters Corporation
  • F. Hoffmann-La Roche Ltd.
  • BD (Becton, Dickinson and Company)
  • Shimadzu Corporation
  • GE Healthcare Life Sciences
  • Lonza Group Ltd.

New players such as Twist Bioscience and 10x Genomics are leveraging innovative technologies in synthetic biology and single-cell analysis, respectively. Twist Bioscience specializes in synthetic DNA and gene synthesis, contributing to advancements in personalized medicine and biotechnology research. Meanwhile, 10x Genomics focuses on single-cell and spatial genomics solutions, enabling researchers to explore cellular diversity and disease mechanisms with unprecedented detail. Key players dominating the market include Thermo Fisher Scientific and Illumina, Thermo Fisher Scientific leads with its comprehensive portfolio of analytical instruments, reagents, and laboratory equipment, bolstered by strategic acquisitions like Qiagen, enhancing its capabilities in molecular diagnostics and genetic testing. Illumina dominates genomic sequencing technologies, driving innovation through advancements in next-generation sequencing (NGS) platforms and collaborations with pharmaceutical companies for precision medicine initiatives. Collaboratively, Thermo Fisher Scientific partnered with Biognosys to integrate mass spectrometry and proteomics for biomarker discovery in precision medicine. Illumina collaborated with GRAIL for early cancer detection through liquid biopsy tests, leveraging NGS technology to enhance diagnostic accuracy and treatment outcomes. These collaborations and innovations underscore the market leaders' commitment to advancing life sciences through transformative technologies and strategic partnerships.

CEO statements

Marc N. Casper, President and CEO of Thermo Fisher Scientific

"Our teams continue to execute at a high level, driving strong operational and financial performance. We are focused on advancing our mission to enable our customers to make the world healthier, cleaner and safer."

Francis deSouza, President and CEO of Illumina

"We continue to see strong demand for our comprehensive genomic solutions, driven by broad adoption of our sequencing and array platforms."

Robert Friel, Executive Chairman of PerkinElmer

"Our innovative technologies are helping to advance science and improve global health outcomes, positioning PerkinElmer as a leader in diagnostics and discovery solutions."

Mike McMullen, President and CEO of Agilent Technologies

"Agilent's strong performance is a testament to our team's dedication and our commitment to delivering innovative solutions to our customers. We remain focused on driving growth and creating long-term value."

Thomas Joyce, Jr., Chairman and CEO of Danaher Corporation

"We are pleased with the progress across our portfolio, driven by strong execution and ongoing investments in innovation. Our life sciences and diagnostics businesses continue to deliver differentiated solutions to our customers worldwide."

These statements highlight the strategic priorities, market outlooks, and commitments to innovation and customer satisfaction from key executives in the Life Science Tools Market.

Recent Developments

  • In February 2022, Agilent Technologies, Inc. and Biosciences, Inc. collaborated to integrate the AVITI System with SureSelect target enrichment panels, therefore improving customer access to genomic tools.
  • In January 2022, the purchase of the Atara Biotherapeutics T-Cell Operations and Manufacturing (ATOM) facility was announced by FUJIFILM Corporation, indicating a calculated decision to manufacture T-cell immunotherapies and other commercial and clinical treatments locally.
  • In 2021, without regard to a disease's specificity, the BIONDA biomarker database collected comprehensive data on biomarker candidates from a variety of PubMed publications. It obtains data from UniProt, Human Disease Ontology, and PubMed abstracts; automated text mining techniques are used to provide frequent updates.
  • In 2021, DisGeNET, a discovery platform, is one of the largest publicly accessible databases of genes and variations linked to human illnesses. The most recent version of DisGeNET (v7.0) comprises 369,554 variant disease correlations between 194,515 variant and 14,155 illnesses, features, and phenotypes, and 1,134,942 gene-disease associations between 21,671 genes and 30,170 diseases, disorders, and traits.
  • In August 2021, Agilent Technologies, Inc. introduced COVID-19 Severity Test Screening utilizing Agilent Cary 630 FTIR Spectrometer.

Market Segmentation

By Technology

  • Genomic Technology
  • Proteomics Technology
  • Cell Biology Technology
  • Lab Supplies & Technologies
  • Other Analytical & Sample Preparation Technology

By Product

  • Cell Culture Systems & 3D Cell Culture
  • Liquid Chromatography
  • Mass Spectrometry
  • Flow Cytometry
  • Cloning & Genome Engineering
  • Microscopy & Electron Microscopy
  • Next Generation Sequencing
  • PCR & qPCR
  • Nucleic Acid Preparation
  • Nucleic Acid Microarray
  • Sanger Sequencing
  • Transfection Devices & Gene Delivery Technologies
  • NMR
  • Others

By End-use

  • Government & Academic
  • Biopharmaceutical Company
  • Healthcare
  • Industrial Applications
  • Others

By Regions 

  • North America
  • APAC
  • Europe
  • LAMEA
TOC not available, you can contact to us for TOC.
...

Proceed To Buy

USD 4750
USD 3800
USD 2100
USD 2100
USD 7500

FAQ's

The global life science tools market size was measured USD 153.40 billion in 2023 and is projected to grow around USD 349.58 billion by 2033.

The global life science tools market size is growing at a CAGR of 8.58% during the forecast period 2024 to 2033.

The top companies operating in life science tools market are Thermo Fisher Scientific, Inc., Merck KGaA (EMD Millipore), Agilent Technologies, Inc., Danaher Corporation (Beckman Coulter), Bio-Rad Laboratories, Inc.,Illumina, Inc., PerkinElmer, Inc., Qiagen N.V., Bruker Corporation, Waters Corporation.